Roche's antiemetic granisetron HCl (Kytril Injection) has received FDA approval for the prevention and treatment of postoperative nausea and vomiting (PONV). The injection form of granisetron was previously approved only to prevent chemotherapy-induced nausea and vomiting; the oral form had been approved for nausea and vomiting induced by radiation therapy.
A selective blocker of the serotonin 5-HT^sub 3^ receptor, Kytril inhibits receptors on the vagus nerve, reducing or eliminating nausea and vomiting. Possible adverse reactions, which include headache, constipation, weakness, drowsiness, or diarrhea, are usually easily managed with dosage modification or interruption.
Give granisetron just before or during surgery to prevent PONV or after surgery to treat PONY. The recommended dose of Kytril Injection for either indication is 1 mg I.V.
Approval of the prevention indication was based on data from two randomized studies in patients who underwent gynecologic surgery or cholecystectomy and received general anesthesia. Approval of the treatment indication was based on studies of adult surgical patients who underwent general anesthesia with no prophylactic antiemetic treatment and experienced nausea and vomiting within 4 hours after surgery.
Copyright Springhouse Corporation Nov 2002
Provided by ProQuest Information and Learning Company. All rights Reserved